Morepen Laboratories Ltd Stock Price Today (NSE: MOREPENLAB)
Fundamental Score
Morepen Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Morepen Laboratories Ltd share price today is ₹38.85, up +0.00% on NSE/BSE as of 17 February 2026. Morepen Laboratories Ltd (MOREPENLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.38K (Cr). The 52-week high for MOREPENLAB share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 31.50x, MOREPENLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.78% and a debt-to-equity ratio of 0.13.
Morepen Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Morepen Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Morepen Laboratories Share Price: A ROCE Efficiency Analysis
The pharmaceutical industry is currently experiencing a period of intense scrutiny regarding pricing pressures and regulatory hurdles, necessitating a laser focus on operational efficiency. This analysis examines the financial health of Morepen Laboratories Ltd, with a particular emphasis on Return on Capital Employed (ROCE). Currently, the Morepen Laboratories share price stands at ₹36.689999, with a Price-to-Earnings (PE) ratio of 31.5 and a ROCE of 15.08%.
ROCE, a key metric for evaluating profitability relative to capital employed, indicates how effectively Morepen Laboratories is utilizing its resources to generate profits. A ROCE of 15.08% suggests a moderate level of efficiency. To put this in perspective, we must consider sector peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd. While a direct comparison requires deeper data on competitor ROCE, a lower ROCE than peers might signal inefficiencies in capital allocation or operational processes.
A company's ROCE directly influences its economic moat – its ability to sustain a competitive advantage over the long term. A consistently high ROCE, driven by factors such as efficient manufacturing, strong pricing power, or robust supply chain management, strengthens this moat. Conversely, a fluctuating or declining ROCE can erode this advantage, making the company more vulnerable to competition. One can draw inferences regarding the management quality by looking at how efficiently companies like
Mankind Pharma Ltd allocate capital in comparision to Morepen Laboratories Ltd.The PE ratio of 31.5, while standard alone does not give a picture, it is important to compare to the sector average and peers to gauge overall valuation. Further investigation is needed to understand why investors are paying a premium (or discount) for Morepen Laboratories compared to its earnings. Factors like growth expectations, risk perception, and investor sentiment all contribute to this valuation. This financial analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide a structured observational view of Morepen Laboratories' financial performance. This analysis offers an observational view only and does not constitute financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Morepen Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MOREPENLAB across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (15.08%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Consistent Growth Track Record (16.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (23.60% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.13)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-49.02%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-5.97%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-444.19 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Morepen Laboratories Ltd Financial Statements
Comprehensive financial data for Morepen Laboratories Ltd including income statement, balance sheet and cash flow
About MOREPENLAB (Morepen Laboratories Ltd)
Morepen Laboratories Ltd (MOREPENLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹2.38K (Cr). Morepen Laboratories Ltd has delivered a Return on Equity (ROE) of 11.78% and a ROCE of 15.08%. The debt-to-equity ratio stands at 0.13, reflecting the company's capital structure. Investors tracking MOREPENLAB share price can monitor key metrics including P/E ratio, promoter holding of 35.65%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
MOREPENLAB Share Price: Frequently Asked Questions
What is the current share price of Morepen Laboratories Ltd (MOREPENLAB)?
As of 17 Feb 2026, 09:14 am IST, Morepen Laboratories Ltd share price is ₹38.85. The MOREPENLAB stock has a market capitalisation of ₹2.38K (Cr) on NSE/BSE.
Is MOREPENLAB share price Overvalued or Undervalued?
MOREPENLAB share price is currently trading at a P/E ratio of 31.50x, compared to the industry average of 31.77x. Based on this relative valuation, the Morepen Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of MOREPENLAB share price?
The 52-week high of MOREPENLAB share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Morepen Laboratories Ltd share price?
Key factors influencing MOREPENLAB share price include quarterly earnings growth (Sales Growth: -5.97%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Morepen Laboratories Ltd a good stock for long-term investment?
Morepen Laboratories Ltd shows a 5-year Profit Growth of 28.58% and an ROE of 11.78%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.13 before investing in MOREPENLAB shares.
How does Morepen Laboratories Ltd compare with its industry peers?
Morepen Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare MOREPENLAB share price P/E of 31.50x and ROE of 11.78% against the industry averages to determine competitive standing.
What is the P/E ratio of MOREPENLAB and what does it mean?
MOREPENLAB share price has a P/E ratio of 31.50x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is MOREPENLAB performing according to Bull Run's analysis?
MOREPENLAB has a Bull Run fundamental score of 34.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MOREPENLAB belong to?
MOREPENLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Morepen Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for MOREPENLAB?
MOREPENLAB has an ROE of 11.78%, which shows decent profitability but room for improvement. ROE measures how efficiently Morepen Laboratories Ltd generates profits from shareholders capital.
How is MOREPENLAB debt-to-equity ratio and what does it indicate?
MOREPENLAB has a debt-to-equity ratio of 0.13, which indicates conservative financing with low financial risk.
What is MOREPENLAB dividend yield and is it a good dividend stock?
MOREPENLAB offers a dividend yield of 0.46%, meaning you receive ₹0.46 annual dividend for every ₹100 invested in Morepen Laboratories Ltd shares.
How has MOREPENLAB share price grown over the past 5 years?
MOREPENLAB has achieved 5-year growth rates of: Sales Growth 16.26%, Profit Growth 28.58%, and EPS Growth 23.60%.
What is the promoter holding in MOREPENLAB and why does it matter?
Promoters hold 35.65% of MOREPENLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Morepen Laboratories Ltd.
What is MOREPENLAB market capitalisation category?
MOREPENLAB has a market capitalisation of ₹2379 crores, placing it in the Small-cap category.
How volatile is MOREPENLAB stock?
MOREPENLAB has a beta of N/A. A beta > 1 suggests the Morepen Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MOREPENLAB operating profit margin trend?
MOREPENLAB has a 5-year average Operating Profit Margin (OPM) of 8.72%, indicating the company's operational efficiency.
How is MOREPENLAB quarterly performance?
Recent quarterly performance shows Morepen Laboratories Ltd YoY Sales Growth of -5.97% and YoY Profit Growth of -49.02%.
What is the institutional holding pattern in MOREPENLAB?
MOREPENLAB has FII holding of 1.62% and DII holding of 1.49%. Significant institutional holding often suggests professional confidence in the Morepen Laboratories Ltd stock.